Sec Form 3 Filing - Cafico Trust Co Ltd @ Mural Oncology plc - 2023-10-31

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Cafico Trust Co Ltd 2. Issuer Name and Ticker or Trading Symbol Mural Oncology plc [ MURA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) PALMERSTOWN HOUSE, FENIAN STREET 3. Date of Earliest Transaction (MM/DD/YY) 10/31/2023 (Street) DUBLIN, L2DUBLIN 2 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares, nominal value $1.00 per share 2 ( 1 ) D ( 1 ) Euro Deferred Shares, nominal value 1.00 Euro per share 25,000 ( 2 ) D ( 2 ) Preferred Share, nominal value $0.01 per share 1 ( 2 ) D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Cafico Trust Co Ltd PALMERSTOWN HOUSE, FENIAN STREET DUBLIN, L2DUBLIN 2 X Signatures /s/ Mairead Lyons 11/07/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The ordinary shares of Mural Oncology plc ("Mural"), nominal value $1.00 per share, beneficially owned by Cafico Trust Company Limited, constitute 100% of the ordinary shares of Mural. As of the date of this report, Alkermes plc ("Alkermes") has announced its intention to separate its oncology business from the rest of Alkermes by means of a declaration of a dividend in specie, to be effected by the transfer of the oncology business from Alkermes to Mural and the issuance by Mural of ordinary shares to Alkermes shareholders. ( 2 )In connection with the separation of the oncology business, Cafico Trust Company Limited also owns (i) 25,000 Euro deferred shares, nominal value 1.00 Euro per share, and (ii) one preferred share, nominal value $0.01, of Mural.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.